Pradžia › Difuzinė didelė B ląstelių limfoma
Difuzinė didelė B ląstelių limfoma klinikiniai tyrimai JAV ieško dalyvių
101 tyrimai dėl Difuzinė didelė B ląstelių limfoma ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- New York City, NY21 tyrimas
- Baldwin Park, CA19 tyrimai
- Chicago, IL18 tyrimai
- Houston, TX17 tyrimai
- Los Angeles, CA17 tyrimai
- Boston, MA16 tyrimai
- Milwaukee, WI16 tyrimai
- Nashville, TN15 tyrimai
- Portland, OR15 tyrimai
- Philadelphia, PA15 tyrimai
- Durham, NC14 tyrimai
- Dallas, TX13 tyrimai
- Seattle, WA12 tyrimai
- Salt Lake City, UT12 tyrimai
- Washington, DC12 tyrimai
- Denver, CO11 tyrimai
- Cincinnati, OH11 tyrimai
- Cleveland, OH11 tyrimai
- Rochester, MN10 tyrimai
- Atlanta, GA10 tyrimai
- Richmond, VA10 tyrimai
- Columbus, OH9 tyrimai
- Edison, NJ9 tyrimai
- Cedar Rapids, IA9 tyrimai
- Omaha, NE9 tyrimai
- San Antonio, TX8 tyrimai
- Sacramento, CA8 tyrimai
- Greenburgh, NY8 tyrimai
- Jacksonville, FL8 tyrimai
- Louisville, KY8 tyrimai
- San Francisco, CA8 tyrimai
- St. Louis, MO8 tyrimai
- New Haven, CT8 tyrimai
- Grand Rapids, MI8 tyrimai
- Charlottesville, VA7 tyrimai
- Kansas City, MO7 tyrimai
- Miami, FL7 tyrimai
- Indianapolis, IN7 tyrimai
- Aurora, CO7 tyrimai
- Pittsburgh, PA6 tyrimai
Pagal valstiją
- Aidahas4 tyrimai
- Ajova11 tyrimai
- Alabama4 tyrimai
- Arizona13 tyrimai
- Arkansas4 tyrimai
- Džordžija15 tyrimai
- Florida23 tyrimai
- Ilinoisas22 tyrimai
- Indianas9 tyrimai
- Kalifornija42 tyrimai
- Kanzasas7 tyrimai
- Kentukis11 tyrimai
- Koloradas19 tyrimai
- Kolumbijos apskritis4 tyrimai
- Konektikutas8 tyrimai
- Luiziana6 tyrimai
- Masčusetsas16 tyrimai
- Merilendas13 tyrimai
- Minesota16 tyrimai
- Misūris8 tyrimai
- Mičiganas15 tyrimai
- Montana4 tyrimai
- Nebraska9 tyrimai
- Nevada3 tyrimai
- New Jersey13 tyrimai
- New Mexico3 tyrimai
- New York31 tyrimas
- North Carolina20 tyrimai
- North Dakota4 tyrimai
- Ohio23 tyrimai
- Oklahoma5 tyrimai
- Oregon15 tyrimai
- Pennsylvania19 tyrimai
- South Carolina4 tyrimai
- South Dakota3 tyrimai
- Tennessee19 tyrimai
- Texas29 tyrimai
- Utah14 tyrimai
- Virginia17 tyrimai
- Washington17 tyrimai
- Wisconsin19 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06863402Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06834373Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07763210Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06649812Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Renkami dalyviai2 fazė
Amžius nuo 65 iki 99 · Visoms lytims · Atnaujinta 2026-09-29 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06091865A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06890884Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT06784167A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT05757219Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT04002947A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-10 · NCT05272384Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.